Back to Search
Start Over
Supplementary Table 2 from A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Grade 3 or 4 adverse events possibly related to refametinib or sorafenib, occurring in {greater than or equal to}2 patients in either cohort
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....6739762d5f3f88061cfa4f75b3d7bb26
- Full Text :
- https://doi.org/10.1158/1078-0432.22459308